Global packaging machinery expert, Sepha Ltd, has developed the world's first tool-less, vision-based leak detection machine for blister-packs.
Global packaging machinery expert, Sepha Ltd, has developed the world's first tool-less, vision-based leak detection machine for blister-packs at Interpack (Hall 16 Stand E23). Visionscan has been developed to meet growing demand from pharmaceutical blister pack manufacturers for a low cost, yet accurate and modern, leak detection alternative to the blue dye test that can be integrated into their quality control systems.
Visionscan uses high resolution camera imaging technology to detect defects in individual blister pockets and weak seals in less than 60 seconds. Because it is tool-less, 21 CFR Part 11 compliant and capable of detecting defects down to 15 micron, it is ideal for contract and generic manufacturers where speed, accuracy and multiple product change over is required.
Visionscan is a non-contact and non-destructive test method enabling significant cost reductions to be achieved during the manufacturing process. At a time when pharmaceutical manufacturers need to improve quality and reduce costs, Visionscan is the ideal product integrity solution because it achieves both cost reductions and improved leak detection accuracy. Manufacturers, particularly those in emerging markets, are seeking an accurate, flexible, easy to operate non-destructive blisterpack leak detection device. Visionscan meets these requirements because of its competitive price point, high degree of accuracy and flexibility across multiple pack formats should make it the global benchmark in leak detection for pharmaceutical blister packs.
Contact
www.sepha.com
Tel. +44 (0)28 9048 4848
marketing@sepha.com
Clinical Supply Planning in Europe - Balancing Cost, Flexibility and Time
December 19th 2024The packaging and distribution of clinical supplies is a fundamental piece to the overall success of a clinical trial, and advance preparation can help establish a more efficient supply chain. Selecting the best geographical location for those activities, however, depends on the clinical trial protocol, business decisions, and even the investigational medicinal product (IMP) being studied.